Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.
Our key findings can be summarized as follows:
• cancer sites with larger increases in the number of drugs ever approved tended to have larger declines in the number of potential years of life lost before ages 75 and 65. • on average, one additional drug approved for a cancer site reduced the number of potential years of life lost before age 75 by 2.3%. • new cancer drugs reduced the number of potential years of life lost before age 75 at an average annual rate of 0.93% during the period 1999-2014. • cancer drugs approved during 2000-2014 are estimated to have reduced the number of potential years of life lost before age 75 in 2014 by 719,133. • premature mortality in year t is strongly inversely related to the number of drugs approved in years t-3 to t (and earlier years), but unrelated to the number of drugs approved in years t+1 to t+4. • one additional drug approval increases the odds of surviving at least 5 years after diagnosis by 2.4%. • new cancer drugs reduced the number of cancer patient hospital days at an average annual rate of 0.83% during the period 1997-2013. • cancer drugs approved between 1989 and 2005 are estimated to have reduced the number of hospital days in 2013 by 1.55 million, and hospital cost in 2013 by $4.8 billion. • our baseline estimate of the cost per life-year gained in 2014 from cancer drugs approved during 2000-2014 is $7853. If we completely ignore the estimated reductions in old drug and hospital expenditure, the estimated cost per life-year gained is $17,104. Even the higher estimate would imply that, overall, cancer drug innovation has been highly cost-effective, by the standards of the World Health Organization and other authorities.
I. Introduction
The number of drugs approved by the Food and Drug Administration (FDA) for treating cancer has increased substantially during the last 40 years. As shown in Figure 1 , 27 drugs for treating cancer had been approved by the FDA by 1975; that number increased to 153 by 2015.
Moreover, cancer drug innovation has been accelerating: more than 8 times as many new cancer drugs were approved during 2005-2015 as were approved during 1975-1985 (66 vs. 8) . In contrast, as shown in Figure 2 , the number of "non-cancer" drugs launched worldwide has tended to decline.
The rapid growth in the number of drugs for treating cancer has been accompanied by a substantial increase in expenditure on cancer drugs. Data on U.S. sales during 2010-2014 of all cancer drugs and of the 10 largest selling (in 2014) drugs are shown in Table 1 . The average annual growth rate of total expenditure was 7.6%--more than 3.6 times the average annual growth rate of nominal U.S. GDP. This has contributed to a lively debate about the value and cost-effectiveness of new cancer drugs.
While the overall number of drugs for treating cancer has increased, data from the National Cancer Institute (NCI) and the FDA indicate that the size of the increase varied considerably across cancer sites (breast, colon, lung, etc.) . The NCI publishes lists of drugs approved for 39 different types of cancer (National Cancer Institute (2016b) ). The first year in which each drug was first approved by the FDA can be determined from the Drugs@FDA database (Food and Drug Administration (2016c) ). By combining data from these two sources, we can measure the history of pharmaceutical innovation for each type of cancer. This is illustrated by Figure 3 , which shows data on drugs that have been approved by the FDA for the treatment of one type of cancer, acute lymphoblastic leukemia. During the period 1994-2014, the number of drugs ever approved for acute lymphoblastic leukemia increased from 10 to 16. Figure 4 shows the number of drugs ever approved during the same period for four types of cancer. A similar number of (between 9 and 13) drugs had ever been approved for each of the four types in 1994. During the next 20 years, 16 new drugs for non-Hodgkin lymphoma and 17 new drugs for breast cancer were approved, but only 6 new drugs for acute lymphoblastic leukemia and one new drug for Hodgkin lymphoma were approved.
In this study, we will attempt to assess the average cost-effectiveness in the U.S. in 2014 of the drugs that the FDA approved for treating cancer during the period 2000-2014. Cost-effectiveness will be measured as the ratio of the impact of new cancer drugs on medical expenditure to their impact on potential years of life lost (PYLL) due to cancer. 1 To estimate the impact of the drugs approved during the period 2000-2014 on PYLL ("premature mortality") due to cancer in 2014, we will estimate difference-in-differences models using longitudinal data on the cancer sites defined by the National Cancer Institute (2016b). In essence, we will investigate whether there were larger declines in mortality from the cancers that had larger increases in the number of drugs ever approved, controlling for the change in cancer incidence and mean age at time of diagnosis. 2 We will analyze two alternative measures of premature mortality: potential years of life lost before ages 75 and 65. In addition, we will analyze the impact of the number of drugs approved on the 5-year observed survival rate, also controlling for the expected survival rate of non-cancer patients. Some of the estimated models will distinguish between the effects of "priority-review" drugs-drugs that the FDA believes demonstrate "the potential to provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious or life-threatening condition" (FDA (2013))-and "standard-review" drugs-drugs that the FDA believes do not demonstrate such potential.
The effect of drug approvals on cancer mortality may be subject to a lag, so the lag structure of the relationship will be investigated. As a robustness check, we will also test whether mortality depends on future drug approvals.
To determine the impact of new cancer drugs on medical expenditure, we will also estimate difference-in-differences models of hospital utilization. All of the data used to estimate the models of cancer mortality and hospitalization are produced by U.S. government agencies and are publicly available.
In Section II, we describe econometric models of cancer patient outcomes. The data sources used to construct the data to estimate these models are described in Section III.
Empirical results are presented in Section IV. In Section V, we use the estimates along with other data to produce an estimate of the average cost-effectiveness of new cancer drugs. Section VI provides a summary and conclusions.
1 Burnet et al (2005) argued that "years of life lost (YLL) from cancer is an important measure of population burden -and should be considered when allocating research funds." 2 New drug approvals can improve outcomes for 2 reasons. First, the quality of newer products may be higher than the quality of older products, as in "quality ladder" models (see Grossman and Helpman (1991) ). Second, "one of the principal means, if not the principal means, through which countries benefit from international trade is by the expansion of varieties" (Broda and Weinstein (2004) ).
II. Models of premature cancer mortality, survival, and hospitalization
Longevity increase (or declining mortality rates) is a very important part of economic growth, broadly defined. Nordhaus (2005) argued that "improvements in health status have been a major contributor to economic welfare over the twentieth century. To a first approximation, the economic value of increases in longevity in the last hundred years is about as large as the value of measured growth in non-health goods and services." The United Nations' Human Development Index (HDI) is a composite statistic of life expectancy, education, and income per capita indicators, which are used to rank countries into four tiers of human development (United Nations (2016)).
Building on a large collection of previous research by Romer (1990) , Grossman and Helpman (1991) , Aghion and Howitt (1992) , and others, Jones (2002, p. 221 ) presented a model in which "long-run growth is driven by the discovery of new ideas throughout the world." He postulated an aggregate production function in which total output depends on the total stock of ideas available to this economy as well as on physical and human capital.
In general, measuring the number of ideas is challenging. One potential measure is the number of patents, but Patterson (2012, p. 8) noted that only 1% of patent applications made by
Bell Labs "generated [commercial] value." Fortunately, due to FDA regulation, measuring pharmaceutical "ideas" is considerably easier than measuring ideas in general. 3 The measure of pharmaceutical ideas we will use is the number of new molecular entities approved by the FDA.
Since we have precise information about when those ideas reached the market and the diseases to which they apply, we can assess the impact of those ideas on longevity and hospitalization in a difference-in-differences framework. We therefore believe that Nordhaus (2005) 
where PYLL75s,t = the number of years of potential life lost before age 75 due to cancer at site s in year t (t = 1999, 2014) N_APP_1948_ts,t = the number of drugs for cancer at site s approved by the FDA between the end of 1948 and the end of year t 5 CASESs,t = the average annual number of people below age 75 diagnosed with cancer at site s in years t-9 to t AGE_DIAGs,t = the mean age at which people below age 75 were diagnosed with cancer at site s in years t-9 to t αs = a fixed effect for cancer at site s δt = a fixed effect for year t
The standard errors of eq. (1) will be clustered within cancer sites. The data exhibit heteroscedasticity. For example, cancer sites with larger mean premature mortality during 1999-2014 had smaller (positive and negative) annual percentage fluctuations in PYLL75st. Eq. (1) will therefore be estimated by weighted least-squares, weighting by Σt PYLL75st. This specification imposes the property of diminishing marginal productivity of drug approvals.
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The parameter of primary interest is β, the coefficient on the number of drugs that had been approved by the end of year t. Inclusion of year and cancer-site fixed effects controls for the overall change in premature mortality and for stable between-cancer-site differences in premature mortality. A negative and significant estimate of β in eq. (1) would signify that cancer sites for which there was more pharmaceutical innovation had larger declines in premature mortality.
We also control for the average annual number of people below age 75 diagnosed with cancer at site s in years t-9 to t, and their mean age; an increase in mean age at diagnosis is expected to reduce premature mortality. Due to data limitations, eq. (1) does not include other disease-specific, time-varying, explanatory variables. But both a patient-level U.S. study and a longitudinal country-level study have shown that controlling for numerous other potential determinants of longevity does not reduce, and may even increase, the estimated effect of pharmaceutical innovation. The study based on patient-level data (Lichtenberg (2013) ) found that controlling for race, education, family income, insurance coverage, Census region, BMI, smoking, the mean year the person started taking his or her medications, and over 100 medical conditions had virtually no effect on the estimate of the effect of pharmaceutical innovation (the change in drug vintage) on life expectancy. The study based on longitudinal country-level data (Lichtenberg (2014a) ) found that controlling for ten other potential determinants of longevity change (real per capita income, the unemployment rate, mean years of schooling, the urbanization rate, real per capita health expenditure (public and private), the DPT immunization rate among children ages 12-23 months, HIV prevalence and tuberculosis incidence) increased the coefficient on pharmaceutical innovation by about 32%.
Failure to control for non-pharmaceutical medical innovation (e.g. innovation in diagnostic imaging, surgical procedures, and medical devices) is also unlikely to bias estimates of the effect of pharmaceutical innovation on premature mortality, for two reasons. First, more than half of U.S. funding for biomedical research came from pharmaceutical and biotechnology firms (Dorsey et al (2010) ). 6 Much of the rest came from the federal government (i.e. the NIH),
and new drugs often build on upstream government research (Sampat and Lichtenberg (2011)).
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The National Cancer Institute (2015b) says that it "has played an active role in the development of drugs for cancer treatment for 50 years… [and] that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed" at the National Cancer Institute. Second, previous research based on U.S.
data (Lichtenberg (2014b) ) indicates that non-pharmaceutical medical innovation is not positively correlated across diseases with pharmaceutical innovation.
A (simpler) "long-difference" model can be derived from the fixed-effects model (eq.
(1)). Setting t equal to 1999 and 2014 (the first and last years of the sample period) yields eqs.
(2) and ( 
Subtracting ( In addition to estimating the basic model of years of potential life lost before age 75 (eq.
(1)), we will modify and generalize the model in several different ways. These modifications of the model will allow us to (1) determine whether drugs approved at different times in the past have different effects on mortality;
(2) perform a falsification test of whether drug approvals after year t affect mortality in year t; and (3) test whether the approval of priority-review and standard-review drugs (defined below) have different effects on mortality. Now we will discuss these modifications in turn.
Heterogeneous effects of drugs approved at different times in the past. The number of drugs ever approved by the end of year t is the sum of the numbers of drugs approved during subperiods prior to year t. For example, N_APP_1948_ts,t is the sum of the number of drugs approved more than 4 years before and 0-4 years before year t:
where N_APP_1948_t-4s,t = the number of drugs for cancer at site s approved by the FDA between the end of 1948 and the end of year t-4
N_APP_t-4_ts,t = the number of drugs for cancer at site s approved by the FDA between the end of year t-4 and the end of year t Substituting (5) into (1) yields:
ln(PYLL75s,t) = β [N_APP_1948_t-4s,t + N_APP_t-4_ts,t] + γ ln(CASESs,t) + π AGE_DIAGs,t + αs + δt + εs,t
In eq. (6), the marginal effects on mortality of approvals in both periods are constrained to be identical. In the following more general model, the marginal effects on mortality of approvals in the two periods are allowed to differ: ln(PYLL75s,t) = β5+ N_APP_1948_t-4s,t + β0_4 N_APP_t-4_ts,t + γ ln(CASESs,t) + π AGE_DIAGs,t + αs + δt + εs,t
The marginal effects of approvals in the two periods are likely to differ, for several reasons.
There are two reasons to expect the magnitude of β0_4 to be smaller than the magnitude of β5+.
First, as shown in Appendix 1, mean utilization of a drug is lower 0-4 years after approval than it is more than 4 years after approval. Second, there is undoubtedly a lag between utilization of a drug and its impact on mortality. But another factor would tend to make the magnitude of β0_4
larger than the magnitude of β5+: quality improvement. If newer drugs tend to be of higher quality than older drugs, a drug approved 0-4 years ago would reduce mortality more than a drug approved more than 4 years ago, if utilization of the two drugs were equal and if there were no lag from utilization to mortality reduction.
Effect of future drug approvals. Approvals in different years prior to year t may have different effects on mortality in year t. Approvals in years after year t should have no effect on mortality in year t. We will test this by including one additional regressor (N_APP_t_t+4s,t) in the model: ln(PYLL75s,t) = β5+ N_APP_1948_t-4s,t + β0_4 N_APP_t-4_ts,t + βPOST N_APP_t_t+4s,t + γ ln(CASESs,t) + π AGE_DIAGs,t + αs + δt + εs,t
where N_APP_t_t+4s,t = the number of drugs for cancer at site s approved by the FDA between the end of year t and the end of year t+4
Heterogeneous effects of priority-review and standard-review drugs. When the FDA begins its review of a new drug application, it designates the drug as either a priority-review drug or a standard-review drug. 7 Priority review designation is assigned to applications for drugs that are expected to provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies. Significant improvement may be demonstrated by the following examples: (1) evidence of increased effectiveness in treatment, prevention, or diagnosis of condition; (2) elimination or substantial reduction of a treatment-limiting drug reaction; (3) documented enhancement of patient compliance that is expected to lead to an improvement in serious outcomes; or (4) evidence of safety and effectiveness in a new subpopulation. Standard review designation is assigned to applications for drugs that do not meet the priority-review designation criteria. 8 We will estimate the following version of eq. (1) that distinguishes between priorityreview and standard-review drugs:
ln(PYLL75s,t) = βPRI N_PRI_1948_ts,t + βSTD N_STD_1948_ts,t + γ ln(CASESs,t) + π AGE_DIAGs,t + αs + δt + εs,t
where N_PRI_1948_ts,t = the number of priority-review drugs for cancer at site s approved by the FDA between the end of 1948 and the end of year t N_STD_1948_ts,t = the number of standard-review drugs for cancer at site s approved by the FDA between the end of 1948 and the end of year t
b. 5-year observed survival rate model
In addition to estimating the premature mortality models described above, we will estimate models of the 5-year survival rate. The observed survival rate is the probability of surviving from all causes of death for a group of cancer patients under study. For example, it is the probability that a person diagnosed with cancer at the end of 2008 was still alive at the end of 2013.
Between 2000 and 2008, the 5-year observed survival rate for all cancer sites combined increased from 55.1% to 59.0%. However, the National Cancer Institute (2015a) points out that "certain factors may cause survival times to look like they are getting better when they are not.
These factors include lead-time bias and overdiagnosis."
Lead-time bias. Survival time for cancer patients is usually measured from the day the cancer is diagnosed until the day they die. Patients are often diagnosed after they have signs and symptoms of cancer. If a screening test leads to a diagnosis before a patient has any symptoms, the patient's survival time is increased because the date of diagnosis is earlier. This increase in survival time makes it seem as though screened patients are living longer when that may not be happening. 9 This is called lead-time bias. It could be that the only reason the survival time appears to be longer is that the date of diagnosis is earlier for the screened patients. But the screened patients may die at the same time they would have without the screening test. Over-diagnosis. Sometimes, screening tests find cancers that don't matter because they would have gone away on their own or never caused any symptoms. These cancers would never have been found if not for the screening test. Finding these cancers is called overdiagnosis. Over-diagnosis can make it seem like more people are surviving cancer longer, but in reality, these are people who would not have died from cancer anyway.
To guard against the risk that lead-time bias and over-diagnosis could bias our estimates of the effect of pharmaceutical innovation on observed cancer survival, we will control for (changes in) the number of people diagnosed (incidence) and for the expected survival rate-the survival probability of a population similar to the patient group with respect to age, sex, race, and calendar year but free of the specific disease under study (Ederer et al (1961) ). We will estimate the following model:
where Eq. (10) will be estimated by weighted least-squares, weighting by CASESs,t. The standard errors of eq. (10) will be clustered within cancer sites.
9 Some studies have found no mortality benefit from more intensive screening. For example, data from the Prostate, Lung, Colorectal and Ovarian randomized screening trial showed that, after 13 years of follow up, men who underwent annual prostate cancer screening with prostate-specific antigen testing and digital rectal examination had a 12 percent higher incidence of prostate cancer than men in the control group but the same rate of death from the disease. No evidence of a mortality benefit was seen in subgroups defined by age, the presence of other illnesses, or pre-trial PSA testing (National Cancer Institute (2012)). 
where HOSP_DAYSs,t = the number of hospital days in year t (t = 1998, 2013) for patients whose principal diagnosis was cancer at site s Eq. (11) will be estimated by weighted least-squares, weighting by Σt HOSP_DAYSs,t. The standard errors of eq. (11) will be clustered within cancer sites.
III. Data sources
Premature mortality. Data on years of potential life lost before ages 75 and 65, by cancer site and year (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , were constructed from data obtained from the Compressed Mortality database (Centers for Disease Control and Prevention (2016a)). In that database, most deaths are reported in 10-year age groups. We assumed that deaths in an age group occur at the midpoint of the age group, e.g. deaths in age group 55-64 occur at age 60.
Drug approvals by cancer site. Lists of drugs approved by the FDA for each type of cancer were obtained from the National Cancer Institute (2016b). The drugs@FDA database (Food and Drug Administration (2016c) ) was used to determine the year in which each of these drugs was first approved by the FDA, and whether the drug was designated as priority-review or standardreview.
Cancer incidence and mean age at diagnosis. Annual data on the number of people diagnosed in SEER 9 registries with each type of cancer were obtained from SEER Research Data (National Cancer Institute (2016c)). Table 3 . Data on the number of drugs ever approved by the FDA, by cancer site and year , are shown in Table 4 .
IV. Empirical results
a. Premature mortality model estimates
Estimates of models of potential years of life lost before age 75 (eqs. (1), (7), (8), and (9)) are presented in Table 5a . All models include ln(CASES), AGE_DIAG, and cancer-site fixed effects; estimates of these parameters are not shown to conserve space. As expected, in all models, the coefficient on ln(CASES) is positive and significant, and the coefficient on AGE_DIAG is negative and significant. The estimation procedure we use (PROC GENMOD in SAS) normalizes the final year fixed effect to be equal to zero, so ∆δ denotes the difference between the initial and final year fixed effects, e.g. δ1999 -δ2014.
In models 1-4, the initial and final years are 1999 and 2014, respectively. These models are based on the full time span of the mortality data, but they don't allow us to perform the falsification test based on future drug approvals. In models 5-10, the initial and final years are 1999 and 2010, respectively; the falsification tests are performed in models 9 and 10.
Model 1 in Table 5a provides an estimate of ∆δ (= δ1999 -δ2014) from eq. (1) when N_APP_1948_t is excluded from the equation. This is an estimate of the weighted mean change of ln(PYLL75), controlling for the changes in ln(CASES) and AGE_DIAG, but not controlling for (or holding constant) N_APP_1948_t, i.e. in the presence of pharmaceutical innovation. It indicates that, controlling for the changes in ln(CASES) and AGE_DIAG, PYLL75 declined by 8.0% between 1999 and 2014.
Model 2 provides estimates of eq. (1) when N_APP_1948_t is included in the equation.
As expected, the coefficient on N_APP_1948_t is negative and highly significant (p-value = 0.0005), indicating that cancer sites with larger increases in the number of drugs ever approved tended to have larger declines in PYLL75. The point estimate of this coefficient implies that, on average, one additional drug approved for a condition reduced PYLL75 by 2.3%. Figure 5 shows the correlation across cancer sites between the 1999-2014 change in the number of drugs ever approved (= the number of drugs approved during 2000-2014) and the 1999-2014 change in the log of PYLL75, controlling for the changes in incidence and mean age at diagnosis. 10 During the period 1999-2014, PYLL75 due to all types of cancer increased by 4.3%, from 4.23 million to 4.42 million (Centers for Disease Control and Prevention (2016b)). The population below age 75 increased by 15.4% (from 256.4 million to 299.0 million) during that period, so the premature cancer mortality rate declined by 11.0% (from 1650 to 1477 per 100,000 population). The weighted mean number of drugs approved during 2000-2014 was 6.07, so the estimates of model 2 imply that in the absence of pharmaceutical innovation, PYLL75 due to all types of cancer would have increased by 18.3% (= 4.3% + (.023 * 6.07)), and that the premature cancer mortality rate would have increased by 2.9% (= 18.3% -15.4%), although the latter increase is probably not statistically significantly different from zero. Also, new cancer drugs reduced PYLL75 at an average annual rate of 0.93% (= (.023 * 6.07) / 15) during the period 1999-2014.
Model 3 in Table 5a corresponds to eq. (9), which distinguishes between priority-review and standard-review drugs. The difference between the coefficients on priority-review and standard-review drugs is not statistically significant, so we are unable to reject the null hypothesis that the two types of drugs had equal effects on PYLL75. Model 4 corresponds to eq.
(7), which distinguishes between drugs approved more than 4 years before year t and drugs approved 0-4 years before year t. The difference between the coefficients on drugs approved in the two periods is not statistically significant.
In models 5-10 of Table 5a , the initial and final years are 1999 and 2010. The estimate of the N_APP_1948_t coefficient in model 6 is larger and more significant than the estimate in model 2 (based on a longer sample period). Models 7 and 8 show that the differences between the coefficients on priority-review and standard-review drugs and between the coefficients on drugs approved more than 4 years before and drugs approved 0-4 years before are again not statistically significant.
Models 9 and 10 include the number of drugs approved 0-4 years after year t. Model 9
does not distinguish between drugs approved more than 4 years before and drugs approved 0-4 years before year t; model 10 does. As expected, the coefficient on the number of drugs approved 0-4 years after year t is not significant in either model. In contrast, in model 10 the coefficient on the number of drugs approved 0-4 years before year t is negative and highly significant. Table 5b presents estimates of models similar to those presented in Table 5a , but in Table   5b the estimates are of models of potential years of life lost before age 65 (PYLL65), rather than age 75. The estimates in Table 5b are qualitatively similar to the estimates in Table 5a : the change in log(PYLL65) is strongly inversely related across cancer sites to the number of new drugs approved; the differences between the coefficients on priority-review and standard-review drugs and between the coefficients on drugs approved more than 4 years before and drugs approved 0-4 years before are not statistically significant; and in model 10 the coefficient on the number of drugs approved 0-4 years after year t is not significant, whereas the coefficient on the number of drugs approved 0-4 years before year t is negative and highly significant.
b. 5-year observed survival rate model estimates
Estimates of models of the observed 5-year survival rate (eq. (10)) are presented in Observations are weighted by number of patients diagnosed. All models in Table 6 include ln(CASES), ln(SURV_EXP/(1 -SURV_EXP)), and cancer-site fixed effects. As expected, the coefficients on ln(CASES) and ln(SURV_EXP/(1 -SURV_EXP)) are both positive and highly significant in all models: observed survival increased more for cancers that had larger increases in the number of people diagnosed and larger increases in expected survival (e.g. due to earlier diagnosis).
Model 1 of Table 6 Model 3 distinguishes between priority-review and standard-review drugs. The coefficient on the former is positive and highly significant, whereas the coefficient on the latter is negative and marginally significant; the difference between the coefficients is highly significant.
Model 4 distinguishes between drugs approved more than 4 years before and drugs approved 0-4 years before. The coefficients on both variables are positive and significant, but the coefficient on more recent drug approvals is significantly larger. Model 5 distinguishes between drugs approved more than 8 years before and drugs approved 0-8 years before. Once again, the coefficients on both variables are positive and significant, but in this case the difference between the coefficients is not statistically significant.
c. Hospital days model estimates
Now we will present estimates of several versions of the model of cancer patient hospital days (eq. (11)). The initial and final years of this analysis are 1997 and 2013, respectively.
During that period, the number of cancer patient hospital days declined 22.1%, from 11.7 million to 9.1 million, despite the fact that the average annual number of patients diagnosed with cancer in SEER 9 registries increased by 29%. Model 1 of Table 7 indicates that, holding constant the number of patients diagnosed and their mean age, the number of cancer patient hospital days declined 32% (= 1 -exp(δ2013 -δ1997)). Model 2 includes the number of drugs approved until
year t. The coefficient on this variable is negative, as expected, but only marginally significant (p-value = 0.077). Model 3 distinguishes between priority-review and standard-review drugs;
the difference between these coefficients is not significant. Model 4 distinguishes between drugs approved more than 4 years before and drugs approved 0-4 years before. Only the coefficient on the number of drugs approved more than 4 years before is statistically significant. Model 5 distinguishes between drugs approved more than 8 years before and drugs approved 0-8 years before. Only the coefficient on the number of drugs approved more than 8 years before is statistically significant. The estimate of (δ1997 -δ2013) in model 5 implies that, in the absence of (lagged) pharmaceutical innovation (i.e. holding constant the number of drugs approved 8 years before, as well as the number of patients diagnosed and their mean age), the number of hospital days would have declined by 19.1%. Thus we estimate that lagged pharmaceutical innovation resulted in a 13.3% decline in the number of cancer patient hospital days during the period 1997-2013. Also, new cancer drugs reduced the number of cancer patient hospital days at an average annual rate of 0.83% (= 13.3% / 16) during the period 1997-2013.
V. Cost-effectiveness estimation
Now we will use some of the estimates described in the previous section along with some other data to produce a baseline estimate of the average cost-effectiveness in 2014 of cancer drugs approved by the FDA during the period 2000-2014. The cost-effectiveness measure we will use is cost per life-year gained: the ratio of the cost in 2014 of drugs approved during the period 2000-2014 (net of rebates and two types of "cost offsets") to the number of life-years gained in 2014 attributable to those drugs. 11
Calculation of cost-effectiveness is described in However, the net social cost of these drugs is considerably lower than that, for three reasons:
rebates, reduced expenditure on old drugs, and reduced hospital expenditure. We address these in turn.
Rebates. Drug rebates are believed to be pervasive, but are notoriously difficult to measure.
Herper (2012) to net (post-rebate) sales figures (in company financial statements). Based on that methodology, he estimated that the weighted average rebate rate was 25%. 13 We therefore assume that rebates on post-1999 cancer drugs amounted to $5.5 billion (line 4 of Table 8 ). Therefore, net sales of these drugs was $16.4 billion.
Reduced expenditure on old drugs. Lichtenberg (2014c, p. 465) Reduced hospital expenditure. The estimate of ∆δ in model 1 of Table 7 implies that, holding constant the number of patients diagnosed and their mean age, HOSP_DAYS declined by 32.4% (= exp(-∆δ) -1) between 1997 and 2013. In 1997, HOSP_DAYS was 11.7 million, so this 20 represents a HOSP_DAYS reduction of 3.78 million (= 32.4% * 11.7 million). The estimate of ∆δ in model 5 of Table 7 . This is shown in line 6 of Table 8 .
As shown in line 7, the estimated net social cost of post-1999 cancer drugs in 2014, after accounting for rebates and reduced expenditure on old drugs and hospital care, is $7.5 billion.
This represents expenditure on all patients. We want to estimate expenditure on patients below the age of 75, because the denominator of the cost-effectiveness ratio we will use is life-years gained before age 75. SEER data indicate that about 75% of cancer patients are diagnosed before the age of 75. As shown in line 8, we will assume that 75% of the net cost of post-1999 cancer drugs in 2014 was on patients below the age of 75, 15 so net expenditure on these patients was $5.6 billion.
The estimates in Table 5 can be used to calculate the number of life-years gained before age 75 in 2014 from cancer drugs approved during 2000-2014, controlling for changes in incidence and mean age at diagnosis. The estimate of ∆δ in model 1 of Table 5a implies that, holding constant the number of patients diagnosed and their mean age, PYLL75 declined by 7.6% (= exp(-∆δ) -1) between 1999 and 2014. In 1999, PYLL75 was 4.229 million, so this represents a PYLL75 reduction of 323,186 (= 7.6% * 4.229 million). The estimate of ∆δ in model 2 of Table 5a implies that, in the absence of pharmaceutical innovation, PYLL75 would have increased by 9.4%, or 395,947 (= 9.4% * 4.229 million). Hence, as shown in line 9 of 14 The aggregate cost of cancer patient hospitalization was $27.9 billion, and the aggregate number of hospital days was 9.1 million (Agency for Healthcare Research and Quality (2016)). Costs tend to reflect the actual costs of production, while charges represent what the hospital billed for the case. Total charges were converted to costs using cost-to-charge ratios based on hospital accounting reports from the Centers for Medicare and Medicaid Services (CMS). Hospital charges is the amount the hospital charged for the entire hospital stay. It does not include professional (MD) fees. Charges are not necessarily how much was reimbursed. 15 The true fraction of expenditure could be higher or lower. Treatments given to younger patients could be more expensive; on the other hand, people diagnosed before age 75 may continue to receive treatments after age 75. (2000)). The World Health Organization considers interventions whose cost per quality-adjusted life-year (QALY) gained is less than 3 times per capita GDP to be costeffective, and those whose cost per QALY gained is less than per capita GDP to be highly costeffective (World Health Organization (2016) 
VI. Summary and conclusions
The number of drugs approved by the FDA for treating cancer has increased substantially during the last 40 years. Moreover, cancer drug innovation has been accelerating: more than 8 times as many new cancer drugs were approved during 2005-2015 as were approved during 1975-1985 (66 vs. 8 In this study, we attempted to assess the average cost-effectiveness in the U.S. in 2014 of new cancer drugs approved by the FDA during 2000-2014. Cost-effectiveness was measured as the ratio of the impact of new cancer drugs on medical expenditure to their impact on potential years of life lost due to cancer. We used a difference-in-difference research design: we investigated whether there were larger declines in premature mortality from the cancers that had larger increases in the number of drugs ever approved, controlling for the change in cancer incidence and mean age at time of diagnosis. The vast majority of the data we relied on are publicly available.
• cancer sites with larger increases in the number of drugs ever approved tended to have larger declines in the number of potential years of life lost before ages 75 and 65. • on average, one additional drug approved for a cancer site reduced the number of potential years of life lost before age 75 by 2.3%. • new cancer drugs reduced the number of potential years of life lost before age 75 at an average annual rate of 0.93% during the period 1999-2014. • cancer drugs approved during 2000-2014 are estimated to have reduced the number of potential years of life lost before age 75 in 2014 by 719,133 • premature mortality in year t is strongly inversely related to the number of drugs approved in years t-3 to t (and earlier years), but unrelated to the number of drugs approved in years t+1 to t+4. • one additional drug approval increases the odds of surviving at least 5 years after diagnosis by 2.4%. • new cancer drugs reduced the number of cancer patient hospital days at an average annual rate of 0.83% during the period 1997-2013. • cancer drugs approved between 1989 and 2005 are estimated to have reduced the number of hospital days in 2013 by 1.55 million, and hospital cost in 2013 by $4.8 billion. • our baseline estimate of the cost per life-year gained in 2014 from cancer drugs approved during 2000-2014 is $7853. If we completely ignore the estimated reductions in old drug and hospital expenditure, the estimated cost per life-year gained is $17,104. Even the higher estimate would imply that, overall, cancer drug innovation has been highly cost-effective, by the standards of the World Health Organization and other authorities.
This study is subject to a number of limitations. The measure of pharmaceutical innovation we used is based on FDA-approved indications of cancer drugs; off-label uses of drugs were not accounted for. The primary outcome measure analyzed was life-years gained, rather than quality-adjusted life-years gained. We could not control for cancer-site-specific non-pharmaceutical medical innovations. Although these are likely to be less important sources of longevity increase than new cancer drugs and may not be correlated with them, measuring and controlling for other medical innovations would be desirable.
Appendix 1
The cancer drug age-utilization profile
We used annual data for the period 2010-2014 on 86 cancer drugs (molecules) to provide evidence about the drug age-utilization profile, by estimating the following model:
where N_SUmn = the number of standard units of molecule m sold in the U.S. n years after it was approved by the FDA (n = 0, 1,…, 25) ρm = a fixed effect for molecule m πn = a fixed effect for age n
The expression exp(πn -π9) is a "relative utilization index": it is the mean ratio of the quantity of a cancer drug sold n years after it was approved to the quantity of the same drug sold 9 years after it was approved.
Estimates of the "relative utilization index" are shown in Appendix Figure 1 . These estimates indicate that it takes about 9 years for a cancer drug to attain its peak level of utilization. The number of standard units 9 years after FDA approval is about twice as great as the number of standard units one year after FDA approval. Moreover, Appendix Figure 1 provides a conservative estimate of the slope of the age-utilization profile, because there was zero utilization of some molecules in the first few years after they were first listed. 17
United Nations ( (4)). Bubble size is proportional to mean PYLL75. 1988-1997 2003-2012 1988-1997 2003-2012 1997 2013 Table 5b Weighted least-squares estimates of models of potential years of life lost before age 65 Model 5 Table 6 Weighted least-squares estimates of models of the observed 5-year survival rate (eq. (10) Weighted least-squares estimates of models of the number of hospital days (eq. (11)) (2015) $32,300,000,000
(2) Fraction of total expenditure on post-1999 drugs Author's calculations based on IMS MIDAS data 67.7%
(3) Expenditure (before rebates) on post-1999 cancer drugs in 2014 (1) * (2) $21,867,100,000
(4) Rebates on post-1999 drugs, assuming 25% rebate rate (Herper (2012) ) 25% * (3) $5,466,775,000
(5) Reduction in old drug cost (assumed to be 25% of new drug cost) (Lichtenberg (2014c)) 25% * ((3) -(4)) $4,100,081,250 (6) Hospital cost reduction
Author's calculations based on estimates of models 1 and 5 in Table 6. $4,770,000,000 (7) Net expend--all ages (3) -((4) + (5) + (6)) $7,530,243,750 (8) Net expend--below age 75 (assumed to be 75% of net expenditure for all ages) 75% * (7) $5,647,682,813 (9) Life-years before age 75 gained, controlling for incidence and mean age at diagnosis
Author's calculations based on estimates of models 1 and 2 in Table 5a .
719,133
(10) Cost per life-year gained before age 75 (9) / (8) $7,853 Number of years after approval Appendix Figure 1 Mean ratio of the quantity of a cancer drug sold n years after approval to the quantity of the same drug sold 9 years after approval
